% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kohle:1007669,
      author       = {Kohle, Felix and Madlener, Marie and Bruno, Emanuel F. and
                      Fink, Gereon R. and Limmroth, Volker and Burghaus, Lothar
                      and Malter, Michael P.},
      title        = {{S}tatus epilepticus and benzodiazepine treatment: {U}se,
                      underdosing and outcome - insights from a retrospective,
                      multicentre registry},
      journal      = {Seizure},
      volume       = {107},
      issn         = {1059-1311},
      address      = {Oxford [u.a.]},
      publisher    = {Elsevier},
      reportid     = {FZJ-2023-02152},
      pages        = {114 - 120},
      year         = {2023},
      abstract     = {Objective: To explore the reasons for and outcomes of non-
                      or undertreatment with benzodiazepines (BZDs) in status
                      epilepticus (SE).Methods: We retrospectively analysed all SE
                      patients from the urban area of Cologne over two
                      years.Results: 328 SE patients were eligible, and only
                      $72\%$ were initially treated with BZDs. Of these, only
                      $21.6\%$ were treated sufficiently with BZDs according to
                      current guidelines. SE patients not initially treated with
                      BZDs were significantly older, had less often known
                      epilepsy, had a prolonged arrival time to the emergency
                      room, and presented more often with a non-generalised
                      convulsive semiology. Regarding adequate dosages, patients
                      with a generalised convulsive SE seemed to benefit from a
                      sufficient BZD dosing with significantly shortened mean
                      ventilation duration (37.1 to 208 h), decreased mean
                      intensive care unit (1.7 to 5 days) and in-hospital stay
                      (4.1 to 8.8 days). In contrary, aggressive BZD treatment in
                      non-generalised convulsive SE resulted in a longer inpatient
                      stay (9.2 to 5.8 days) and lower favourable outcome rates at
                      discharge $(16\%$ to $63\%).Conclusions:$ The current SE
                      treatment guidelines for first-line BZD therapy in SE were
                      violated in most patients. Sufficient BZD dosing was
                      beneficial in generalised convulsive SE, but not in other
                      forms of SE. SE semiology might be crucial for treatment
                      decisions with BZDs. Further treatment evidence especially
                      in non-generalised convulsive SE is urgently
                      needed.Keywords: Anticonvulsants; Benzodiazepines; Critical
                      care; Guideline adherence; Seizures.},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {5251 - Multilevel Brain Organization and Variability
                      (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5251},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {37004393},
      UT           = {WOS:001031705300001},
      doi          = {10.1016/j.seizure.2023.03.020},
      url          = {https://juser.fz-juelich.de/record/1007669},
}